The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

Lattice degeneration of the retina occurs when your retina gets thinner over time. About 10% of people experience this condition within their lifetime. It does not directly cause vision issues, but ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — Risk factors for rhegmatogenous retinal detachment following cataract surgery include younger age, ...

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...

ANN ARBOR, Mich., April 12, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal ...

Well, it's recommended that most of us get an eye exam about every two years. But you know, the eyes are the window into the body, and many common medical problems can actually be seen in the eyes. Dr ...

No changes in protocol recommended for LUGANO and LUCIA clinical trials –– Masked safety data continues to show no safety signals, consistent ...

The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...